M&A / Deals Avalyn seeks public debut to support new lung drug formulations BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.M&A / DealsRespiratoryRead full story pharminent April 24, 2026 (Last updated: April 25, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. M&A / DealsRespiratoryRead full story Post navigation Previous: Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer ChannelsNext: Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026